William M. Yashar

William M. Yashar

Auto-generated profile, based on publicly available information

William M. Yashar

Knight Cancer Institute, Oregon Health & Science University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in iScience
Verified
Journal Article
Open access
WYWilliam M. Yashar
William M. Yashar
JEJoseph Estabrook
Joseph Estabrook
HHHannah D. Holly
Hannah D. Holly
JSJulia Somers
Julia Somers
ONOlga Nikolova
Olga Nikolova
EDEmek Demir
Emek Demir
Dysregulation of normal transcription factor activity is a common driver of disease. Therefore, the detection of aberrant transcription factor activity is important to understand disease pathogenesis. We have developed Priori, a method to predict transcription factor activity from RNA sequencing data. Priori has two key advantages over existing methods. First, Priori utilizes literature-supported regulatory information to identify transcription factor-target gene relationships. It then applies linear models to determine the impact of transcription factor regulation on the expression of its target genes. Second, results from a third-party benchmarking pipeline reveals that Priori detects aberrant activity from 124 single-gene perturbation experiments with higher sensitivity and specificity than 11 other methods. We applied Priori and other top-performing methods to predict transcription factor activity from two large primary patient datasets. Our work demonstrates that Priori uniquely discovered significant determinants of survival in breast cancer and identified mediators of drug response in leukemia.

19 May 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
BCBrittany M. Curtiss
Brittany M. Curtiss
JVJake VanCampen
Jake VanCampen
JMJommel Macaraeg
Jommel Macaraeg
GKGarth L. Kong
Garth L. Kong
ATAkram Taherinasab
Akram Taherinasab
TBTheodore P. Braun
Theodore P. Braun

16 December 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
TBTheodore P. Braun
Theodore P. Braun
JEJoseph Estabrook
Joseph Estabrook
ZSZachary Schonrock
Zachary Schonrock
BCBrittany M. Curtiss
Brittany M. Curtiss
Lucie DarmuseyLucie Darmusey
Lucie Darmusey
JMJulia E. Maxson
Julia E. Maxson

28 March 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
WYWilliam M. Yashar
William M. Yashar
BCBrittany M. Curtiss
Brittany M. Curtiss
DCDaniel J. Coleman
Daniel J. Coleman
JVJake VanCampen
Jake VanCampen
GKGarth Kong
Garth Kong
TBTheodore P. Braun
Theodore P. Braun
Mutations in Fms-like tyrosine kinase 3 (FLT3) are common drivers in acute myeloid leukemia (AML) yet FLT3 inhibitors only provide modest clinical benefit. Prior work has shown that inhibitors of lysine-specific demethylase 1 (LSD1) enhance kinase inhibitor activity in AML. Here we show that combined LSD1 and FLT3 inhibition induces synergistic cell death in FLT3-mutant AML. Multi-omic profiling revealed that the drug combination disrupts STAT5, LSD1, and GFI1 binding at the MYC blood superenhancer, suppressing superenhancer accessibility as well as MYC expression and activity. The drug combination simultaneously results in the accumulation of repressive H3K9me1 methylation, an LSD1 substrate, at MYC target genes. We validated these findings in 72 primary AML samples with the nearly every sample demonstrating synergistic responses to the drug combination. Collectively, these studies reveal how epigenetic therapies augment the activity of kinase inhibitors in FLT3-ITD (internal tandem duplication) AML. Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.

21 November 2023 in Proteomics
Verified
Journal Article
Open access
JSJulia Somers
Julia Somers
MFMadeleine Fenner
Madeleine Fenner
GKGarth Kong
Garth Kong
DTDharani Thirumalaisamy
Dharani Thirumalaisamy
WYWilliam M. Yashar
William M. Yashar
EDEmek Demir
Emek Demir
For decades, molecular biologists have been uncovering the mechanics of biological systems. Efforts to bring their findings together have led to the development of multiple databases and information systems that capture and present pathway information in a computable network format. Concurrently, the advent of modern omics technologies has empowered researchers to systematically profile cellular processes across different modalities. Numerous algorithms, methodologies, and tools have been developed to use prior knowledge networks (PKNs) in the analysis of omics datasets. Interestingly, it has been repeatedly demonstrated that the source of prior knowledge can greatly impact the results of a given analysis. For these methods to be successful it is paramount that their selection of PKNs is amenable to the data type and the computational task they aim to accomplish. Here we present a five‐level framework that broadly describes network models in terms of their scope, level of detail, and ability to inform causal predictions. To contextualize this framework, we review a handful of network‐based omics analysis methods at each level, while also describing the computational tasks they aim to accomplish.

12 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
WYWilliam M Yashar
William M Yashar
GKGarth Kong
Garth Kong
JVJake VanCampen
Jake VanCampen
BSBrittany M Smith
Brittany M Smith
DCDaniel J Coleman
Daniel J Coleman
TBTheodore P Braun
Theodore P Braun
Genome-wide mapping of the histone modification landscape is critical to understanding tran-scriptional regulation. Cleavage Under Targets and Tagmentation (CUT&Tag) is a new method for profiling the localization of covalent histone modifications, offering improved sensitivity and decreased cost compared with Chromatin Immunoprecipitation Sequencing (ChIP-seq). Here, we present GoPeaks, a peak calling method specifically designed for histone modification CUT&Tag data. GoPeaks implements a Binomial distribution and stringent read count cut-off to nominate candidate genomic regions. We compared the performance of GoPeaks against commonly used peak calling algorithms to detect H3K4me3, H3K4me1, and H3K27Ac peaks from CUT&Tag data. These histone modifications display a range of peak profiles and are frequently used in epigenetic studies. We found GoPeaks robustly detects genome-wide histone modifications and, notably, identifies H3K27Ac with improved sensitivity compared to other standard peak calling algorithms.